Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM)

Trial Profile

Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Fotemustine (Primary) ; Temozolomide
  • Indications Brain metastases; Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2019 Status changed from completed to discontinued.
    • 10 May 2018 Status changed from active, no longer recruiting to completed, as reported in an article published in the BMC Cancer.
    • 12 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top